JP2022519385A5 - - Google Patents

Info

Publication number
JP2022519385A5
JP2022519385A5 JP2021546382A JP2021546382A JP2022519385A5 JP 2022519385 A5 JP2022519385 A5 JP 2022519385A5 JP 2021546382 A JP2021546382 A JP 2021546382A JP 2021546382 A JP2021546382 A JP 2021546382A JP 2022519385 A5 JP2022519385 A5 JP 2022519385A5
Authority
JP
Japan
Prior art keywords
day
composition according
amino
therapeutic agent
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021546382A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519385A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/051030 external-priority patent/WO2020165733A1/en
Publication of JP2022519385A publication Critical patent/JP2022519385A/ja
Publication of JP2022519385A5 publication Critical patent/JP2022519385A5/ja
Pending legal-status Critical Current

Links

JP2021546382A 2019-02-12 2020-02-10 Tno155及びpd-1阻害剤を含む医薬組合せ Pending JP2022519385A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962804707P 2019-02-12 2019-02-12
US62/804,707 2019-02-12
PCT/IB2020/051030 WO2020165733A1 (en) 2019-02-12 2020-02-10 Pharmaceutical combination comprising tno155 and a pd-1 inhibitor

Publications (2)

Publication Number Publication Date
JP2022519385A JP2022519385A (ja) 2022-03-23
JP2022519385A5 true JP2022519385A5 (cg-RX-API-DMAC7.html) 2023-02-20

Family

ID=69724012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021546382A Pending JP2022519385A (ja) 2019-02-12 2020-02-10 Tno155及びpd-1阻害剤を含む医薬組合せ

Country Status (13)

Country Link
US (1) US20220160706A1 (cg-RX-API-DMAC7.html)
EP (1) EP3923940B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022519385A (cg-RX-API-DMAC7.html)
KR (1) KR20210126652A (cg-RX-API-DMAC7.html)
CN (1) CN113395967A (cg-RX-API-DMAC7.html)
AU (1) AU2020222295B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021015487A2 (cg-RX-API-DMAC7.html)
CA (1) CA3129031A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002100A1 (cg-RX-API-DMAC7.html)
IL (1) IL284837A (cg-RX-API-DMAC7.html)
MX (1) MX2021009562A (cg-RX-API-DMAC7.html)
TW (1) TW202045172A (cg-RX-API-DMAC7.html)
WO (1) WO2020165733A1 (cg-RX-API-DMAC7.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3856345A1 (en) 2018-09-29 2021-08-04 Novartis AG Process of manufacture of a compound for inhibiting the activity of shp2
IL304526B2 (en) 2018-09-29 2025-05-01 Novartis Ag Production of compounds and preparations for inhibiting the activity of SHP2
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
US12343344B2 (en) 2019-02-12 2025-07-01 Novartis Ag Pharmaceutical combination comprising TNO155 and ribociclib
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
ES3040751T3 (en) 2020-07-08 2025-11-04 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of shp2
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
US20240082218A1 (en) * 2020-12-22 2024-03-14 Novartis Ag Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancers
WO2022133731A1 (en) * 2020-12-22 2022-06-30 Novartis Ag Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers
PE20240088A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras
CN117677619A (zh) * 2021-05-05 2024-03-08 沪亚生物国际有限责任公司 包含shp2抑制剂和pd-1抑制剂的联合疗法
CA3217084A1 (en) * 2021-05-05 2022-11-10 Farbod Shojaei Combination therapies comprising shp2 inhibitors and pd-1 inhibitors
WO2022235822A1 (en) 2021-05-05 2022-11-10 Huabio International, Llc Shp2 inhibitor monotherapy and uses thereof
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202342040A (zh) 2022-02-21 2023-11-01 瑞士商諾華公司 藥物配製物
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗pd-1抗體類和使用彼等之方法
TN2017000554A1 (en) * 2015-07-29 2019-04-12 Novartis Ag Novel combination for use in the treatment of cancer
CN110730678B (zh) * 2017-01-10 2022-07-15 诺华股份有限公司 包含alk抑制剂和shp2抑制剂的药物组合
US12343344B2 (en) * 2019-02-12 2025-07-01 Novartis Ag Pharmaceutical combination comprising TNO155 and ribociclib
CN113382774A (zh) * 2019-02-12 2021-09-10 诺华股份有限公司 包含tno155和krasg12c抑制剂的药物组合

Similar Documents

Publication Publication Date Title
JP2022519375A5 (cg-RX-API-DMAC7.html)
JP2022520079A5 (cg-RX-API-DMAC7.html)
JP5579715B2 (ja) cdk阻害剤および抗悪性腫瘍剤を含む治療用組合せ
CN108601831B (zh) 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途
EP2435041B1 (en) Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
JP2019516733A5 (cg-RX-API-DMAC7.html)
IL300151A (en) Combinations for cancer treatment
JP2012506448A5 (cg-RX-API-DMAC7.html)
JP2023175694A5 (cg-RX-API-DMAC7.html)
JP2019526595A5 (cg-RX-API-DMAC7.html)
JP2017160178A5 (cg-RX-API-DMAC7.html)
JP2018530578A5 (cg-RX-API-DMAC7.html)
CZ20032266A3 (cs) Dávkovací formy pro ošetřování nádorů
JP2019524820A5 (cg-RX-API-DMAC7.html)
Punt New drugs in the treatment of colorectal carcinoma
JP2019506392A5 (cg-RX-API-DMAC7.html)
Kim et al. A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer
JP2023524789A5 (cg-RX-API-DMAC7.html)
JP2019534251A5 (cg-RX-API-DMAC7.html)
JP2021530502A5 (cg-RX-API-DMAC7.html)
JP2025511402A5 (cg-RX-API-DMAC7.html)
JP2024535880A5 (cg-RX-API-DMAC7.html)
JP2023531090A5 (cg-RX-API-DMAC7.html)
JP2015510945A5 (cg-RX-API-DMAC7.html)
RU2021126525A (ru) Фармацевтическая комбинация, содержащая tno155 и ингибитор pd-1